StockUnited StatesNasdaqGM

IOVA

Iovance Biotherapeutics, Inc.

Healthcare · Biotechnology

14.09USD

-0.0500 (-0.35%)

Community sentiment

Not enough data yet

A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.

Members' own stated views, weighted by account age and track record on this site (simulated portfolios and calls). Not a forecast or a price signal. How this is worked out

Only members whose accounts are at least 14 days old and who have a track record on this site (simulated portfolios and calls) count, and bots never do. A take from anyone else is saved and starts to count the day they qualify.
A take fades: it counts half as much after 7 days and drops out after 30.
Members with a strong record count more. Everyone else counts together for a capped share, so many accounts cannot outweigh a few strong ones.
Nothing is shown until 5 qualifying members have taken part, 2 of them with a strong record. It stays an early read until 3 have one and the sample is large enough.
Until 20 members have taken part the marker only says bullish, bearish or mixed, at a fixed spot, and the number of members is given as a band, not a count.
The reading is refreshed about every 30 minutes, so a take you have just made will not move it straight away.
Your own take is private: only the totals are shown, and never who said what.

Description Historical Financials Relative Value Research News Community Room OptionsPrice Chart ↗Fundamental Chart ↗

In $M except per-share	Q2 FY26	Q1 FY26	Q4 FY25*	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24*	Q3 FY24
Revenue	99	71	87	67	60	49	74	59
Cost of Revenue	44	42	43	38	49	43	38	32
Gross Profit	56	29	44	29	11	7	36	27
Operating Income	-52	-81	-73	-95	-114	-121	-87	-89
Net Income	-47	-79	-72	-91	-112	-116	-79	-84
EPS (Diluted)	-$0.11	-$0.19	—	—	-$0.33	-$0.36	-$0.25	-$0.28

* Derived period (computed from FY minus reported quarters). Source: SEC filings (EDGAR)

Fetching financial statements from SEC filings…